Search

दवा प्रतिरोधी संक्रमणों के लिए भारत ने नैफिथ्रोमाइसिन न�

Nafithromycin, India’s first indigenously developed antibiotic for resistant infections, showcases innovation through public-private collaboration.

India must prioritise the development of novel drugs to address the mental health crisis effectively, leveraging its biotechnology and pharmaceutical

Artificial Intelligence (AI) has already made inroads into healthcare. The increasing availability of healthcare data has allowed for the deployment of powerful AI techniques to assist drug development as well as clinical practice. These run the gamut from machine learning (ML) techniques that analyse structured data, to natural language processing (NLP) that can extract meaningful information from unstructured data, such as doctors’ notes. Thi

The treatment of mental health disorders is a difficult task due to the highly subjective nature of each case, the varying efficacy of drugs available, and the social stigma associated with mental illness. In India, the treatment gap is steep, but it can be reduced in a number of ways: through concerted efforts by the biotechnology and pharmaceutical industries on novel drug development; by leveraging allied technologies such as data science, art

Of all cases of rare diseases across the globe, around one-third occur in India. Yet, these diseases—‘rare’ because they affect a relatively small number of people—are hardly given attention in the country. With its resource constraints, India continues to lag in awareness, diagnosis, and drug development relating to such diseases, and there is inadequate medical and scientific research, too. India formulated a National Policy on Rare Dis

मानसिक स्वास्थ्य संबंधी बीमारियों का उपचार बेहद जटिल काम होता है. इसका कारण यह है कि इन बीमारियों की प्रकृति प्रत्येक मामले में अलग-अलग होती है. इसके अलावा उपलब्ध औषधियों क